Neurocrine Biosciences, Inc (NBIX) Stock AnalysisNBIXStock AnalysisNeurocrine Biosciences, Inc

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. It is engaged in discovering, developing, and commercializing life-changing treatments for patients with under-addressed neurological, psychiatric, endocrine, and immunological disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its first-in-class commercial portfolio includes INGREZZA (valbenazine) and CRENESSITY (crinecerfont). It also offers VYKAT XR (diazoxide choline) extended-release tablets, for the treatment of hyperphagia in adults and pediatric patients four years of age and older with Prader-Willi syndrome (PWS). Its pipeline includes direclidine / (M4 Agonist), osavampator॥ / (AMPA PAM) and others. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Neurocrine Biosciences Inc is currently at a price of $154.06, with a forward P/E ratio of 23.15, indicating that it may be overvalued compared to its earnings potential. The RSI is at 41.60, suggesting that the stock is nearing oversold territory but is not yet a strong buy signal. The recent acquisition of Soleno Therapeutics has raised safety concerns that could negatively impact investor confidence, which is a significant risk to consider.

13 analysts cover NBIX: 13 rate it Buy, 0 Hold and 0 Sell. The average price target is 179.68.